101 related articles for article (PubMed ID: 28642028)
1. Discovery of novel 5-oxa-2,6-diazaspiro[3.4]oct-6-ene derivatives as potent, selective, and orally available somatostatin receptor subtype 5 (SSTR5) antagonists for treatment of type 2 diabetes mellitus.
Hirose H; Yamasaki T; Ogino M; Mizojiri R; Tamura-Okano Y; Yashiro H; Muraki Y; Nakano Y; Sugama J; Hata A; Iwasaki S; Watanabe M; Maekawa T; Kasai S
Bioorg Med Chem; 2017 Aug; 25(15):4175-4193. PubMed ID: 28642028
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel somatostatin receptor subtype 5 (SSTR5) antagonists: Pharmacological studies and design to improve pharmacokinetic profiles and human Ether-a-go-go-related gene (hERG) inhibition.
Yamasaki T; Hirose H; Yamashita T; Takakura N; Morimoto S; Nakahata T; Kina A; Nakano Y; Okano Tamura Y; Sugama J; Odani T; Shimizu Y; Iwasaki S; Watanabe M; Maekawa T; Kasai S
Bioorg Med Chem; 2017 Aug; 25(15):4153-4162. PubMed ID: 28622905
[TBL] [Abstract][Full Text] [Related]
3. Novel, non-peptidic somatostatin receptor subtype 5 antagonists improve glucose tolerance in rodents.
Sprecher U; Mohr P; Martin RE; Maerki HP; Sanchez RA; Binggeli A; Künnecke B; Christ AD
Regul Pept; 2010 Jan; 159(1-3):19-27. PubMed ID: 19761802
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a novel series of GPR119 agonists: Design, synthesis, and biological evaluation of N-(Piperidin-4-yl)-N-(trifluoromethyl)pyrimidin-4-amine derivatives.
Kubo O; Takami K; Kamaura M; Watanabe K; Miyashita H; Abe S; Matsuda K; Tsujihata Y; Odani T; Iwasaki S; Kitazaki T; Murata T; Sato K
Bioorg Med Chem; 2021 Jul; 41():116208. PubMed ID: 34010766
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a novel series of indolinylpyrimidine-based GPR119 agonists: Elimination of ether-a-go-go-related gene liability using a hydrogen bond acceptor-focused approach.
Kamaura M; Kubo O; Sugimoto H; Noguchi N; Miyashita H; Abe S; Matsuda K; Tsujihata Y; Odani T; Iwasaki S; Murata T; Sato K
Bioorg Med Chem; 2021 Mar; 34():116034. PubMed ID: 33548803
[TBL] [Abstract][Full Text] [Related]
6. Selective somatostatin receptor 5 inhibition improves hepatic insulin sensitivity.
Tamura YO; Sugama J; Abe SI; Shimizu Y; Hirose H; Watanabe M
Pharmacol Res Perspect; 2023 Feb; 11(1):e01043. PubMed ID: 36585794
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus.
Park K; Lee BM; Hyun KH; Lee DH; Choi HH; Kim H; Chong W; Kim KB; Nam SY
Bioorg Med Chem; 2014 Apr; 22(7):2280-93. PubMed ID: 24588963
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel diarylketoxime derivatives as selective and orally active melanin-concentrating hormone 1 receptor antagonists.
Suzuki T; Kameda M; Ando M; Miyazoe H; Sekino E; Ito S; Masutani K; Kamijo K; Takezawa A; Moriya M; Ito M; Ito J; Nakase K; Matsushita H; Ishihara A; Takenaga N; Tokita S; Kanatani A; Sato N; Fukami T
Bioorg Med Chem Lett; 2009 Sep; 19(18):5339-45. PubMed ID: 19683441
[TBL] [Abstract][Full Text] [Related]
9. Antidiabetic activity of a highly potent and selective nonpeptide somatostatin receptor subtype-2 agonist.
Strowski MZ; Cashen DE; Birzin ET; Yang L; Singh V; Jacks TM; Nowak KW; Rohrer SP; Patchett AA; Smith RG; Schaeffer JM
Endocrinology; 2006 Oct; 147(10):4664-73. PubMed ID: 16857751
[TBL] [Abstract][Full Text] [Related]
10. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.
Ha TY; Kim YS; Kim CH; Choi HS; Yang J; Park SH; Kim DH; Rhee JK
Arch Pharm Res; 2014 May; 37(5):671-8. PubMed ID: 23897163
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of a novel series of orally active, selective somatostatin receptor 2 agonists for the treatment of type 2 diabetes.
Banno Y; Sasaki S; Kamata M; Kunitomo J; Miyamoto Y; Abe H; Taya N; Oi S; Watanabe M; Urushibara T; Hazama M; Niwa SI; Miyamoto S; Horinouchi A; Kuroshima KI; Amano N; Matsumoto SI; Matsunaga S
Bioorg Med Chem; 2017 Nov; 25(21):5995-6006. PubMed ID: 28988629
[TBL] [Abstract][Full Text] [Related]
12. Discovery of phenylsulfonyl acetic acid derivatives with improved efficacy and safety as potent free fatty acid receptor 1 agonists for the treatment of type 2 diabetes.
Li Z; Liu C; Xu X; Qiu Q; Su X; Dai Y; Yang J; Li H; Shi W; Liao C; Pan M; Huang W; Qian H
Eur J Med Chem; 2017 Sep; 138():458-479. PubMed ID: 28689096
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, structure-activity relationship, and pharmacological studies of novel melanin-concentrating hormone receptor 1 antagonists 3-aminomethylquinolines: reducing human ether-a-go-go-related gene (hERG) associated liabilities.
Kasai S; Kamata M; Masada S; Kunitomo J; Kamaura M; Okawa T; Takami K; Ogino H; Nakano Y; Ashina S; Watanabe K; Kaisho T; Imai YN; Ryu S; Nakayama M; Nagisa Y; Takekawa S; Kato K; Murata T; Suzuki N; Ishihara Y
J Med Chem; 2012 May; 55(9):4336-51. PubMed ID: 22490048
[TBL] [Abstract][Full Text] [Related]
14. The discovery of N-((2H-tetrazol-5-yl)methyl)-4-((R)-1-((5r,8R)-8-(tert-butyl)-3-(3,5-dichlorophenyl)-2-oxo-1,4-diazaspiro[4.5]dec-3-en-1-yl)-4,4-dimethylpentyl)benzamide (SCH 900822): a potent and selective glucagon receptor antagonist.
DeMong D; Dai X; Hwa J; Miller M; Lin SI; Kang L; Stamford A; Greenlee W; Yu W; Wong M; Lavey B; Kozlowski J; Zhou G; Yang DY; Patel B; Soriano A; Zhai Y; Sondey C; Zhang H; Lachowicz J; Grotz D; Cox K; Morrison R; Andreani T; Cao Y; Liang M; Meng T; McNamara P; Wong J; Bradley P; Feng KI; Belani J; Chen P; Dai P; Gauuan J; Lin P; Zhao H
J Med Chem; 2014 Mar; 57(6):2601-10. PubMed ID: 24527772
[TBL] [Abstract][Full Text] [Related]
15. Discovery of orally active hepatoselective glucokinase activators for treatment of Type II Diabetes Mellitus.
Xu J; Lin S; Myers RW; Trujillo ME; Pachanski MJ; Malkani S; Chen HS; Chen Z; Campbell B; Eiermann GJ; Elowe N; Farrer BT; Feng W; Fu Q; Kats-Kagan R; Kavana M; McMasters DR; Mitra K; Tong X; Xu L; Zhang F; Zhang R; Addona GH; Berger JP; Zhang B; Parmee ER
Bioorg Med Chem Lett; 2017 May; 27(9):2063-2068. PubMed ID: 28284809
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the progression of type 2 diabetes in the C57BL/6J mouse model by an anti-diabetes herbal formula.
Winters WD; Huo YS; Yao DL
Phytother Res; 2003 Jun; 17(6):591-8. PubMed ID: 12820223
[TBL] [Abstract][Full Text] [Related]
17. Discovery of imidazo[1,2-a]pyridines as potent MCH1R antagonists.
Kishino H; Moriya M; Sakuraba S; Sakamoto T; Takahashi H; Suzuki T; Moriya R; Ito M; Iwaasa H; Takenaga N; Ishihara A; Kanatani A; Sato N; Fukami T
Bioorg Med Chem Lett; 2009 Aug; 19(16):4589-93. PubMed ID: 19615899
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and Structure-activity relationship studies of new thiazole-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes.
Li Z; Qiu Q; Xu X; Wang X; Jiao L; Su X; Pan M; Huang W; Qian H
Eur J Med Chem; 2016 May; 113():246-57. PubMed ID: 26945112
[TBL] [Abstract][Full Text] [Related]
19. Molecular cloning, functional characterization, and chromosomal localization of a human somatostatin receptor (somatostatin receptor type 5) with preferential affinity for somatostatin-28.
Panetta R; Greenwood MT; Warszynska A; Demchyshyn LL; Day R; Niznik HB; Srikant CB; Patel YC
Mol Pharmacol; 1994 Mar; 45(3):417-27. PubMed ID: 7908405
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of 4,7,12,12a-tetrahydro-5H-thieno[3',2':3,4]pyrido[1,2-b]isoquinolines as novel adenosine 5'-monophosphate-activated protein kinase (AMPK) indirect activators for the treatment of type 2 diabetes.
Zhou S; Duan Y; Wang J; Zhang J; Sun H; Jiang H; Gu Z; Tong J; Li J; Li J; Liu H
Eur J Med Chem; 2017 Nov; 140():448-464. PubMed ID: 28987606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
